Author: crjfinlayson

December 5, 2022 Represents PharmaCielo’s first shipment to Africa. Morocco is pioneering the commercialization of cannabinoid products on the African continent and will be a growing market. The Company also announced that it has agreed to issue shares in settlement of certain interest payments and

November 22, 2022 TORONTO, Canada and RIONEGRO, Colombia (November 22, 2022) – PharmaCielo Ltd. (“PharmaCielo”or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced

October 31, 2022 In the first nine months of 2022, PharmaCielo has made shipments to 23 customers in nine countries, with continued growth expected for 2023. The Company has more than doubled Revenue to $3.8 million in the first nine months of 2022, compared to

October 12, 2022 PharmaCielo’s own CFO and board member, Ian Atacan, is on the panel discussing key challenges and opportunities for the global cannabis industry. Watch it today!  https://direc.to/iU_T

October 12, 2022 This is PharmaCielo’s second pharmaceutical grade product shipment to a well-established Latin American pharmaceutical company with operations in Uruguay. TORONTO, Canada and RIONEGRO, Colombia (October 12, 2022) – PharmaCielo Ltd. (“PharmaCielo” orthe “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s

September 15, 2022 Shipment made to an established pharmaceutical distributor and clinical research organization in the Czech Republic, focused on medicinal grade cannabinoids. TORONTO, Canada and RIONEGRO, Colombia Colombia (September 15, 2022) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO,OTCQX: PCLOF), the Canadian parent

September 14, 2022 Colombian government has maintained its commitment to supporting its cannabis producers and building a dominant global export industry. Five tonne quota to grow THC-dominant cannabis strains for export as dried flower will support the fulfillment of current sales agreements, beginning in early

August 30, 2022 The Company continues to grow sales and expects to build momentum through the remainder of 2022 and through 2023, with recent progress in Israel, Brazil and Mexico. PharmaCielo product has been sold in 14 countries to date, and the Company expects to

August 25, 2022 The Company expects to begin exporting dried flower to Israel in early 2023. Israel is one of the largest importers of medical cannabis in the world, with 109,352 active medical patients in 2021 (+35% vs. 2020). TORONTO, Canada and RIONEGRO, Colombia (August

August 4, 2022 The Company has made a pre-commercial shipment of CBD isolate to its Mexican joint venture, to support product development by a Mexican phytotherapeutic company. TORONTO, Canada and RIONEGRO, Colombia (August 4, 2022) – PharmaCielo Ltd. (“PharmaCielo” orthe “Company”) (TSXV: PCLO, OTCQX: PCLOF),